A unique mucin immunoenhancing peptide with antitumor properties

Cancer Research

Volumn 64, Issue 21, 2004, Pages 8077-8084

  Herbert, Lynn M ^a   Grosso, Joseph F ^a   Dorsey Jr , Mantley ^a   Fu, Tihui ^a   Keydar, Iafa ^b   Cejas, Mabel A ^a   Wreschner, Daniel H ^b   Smorodinski, Nechama ^b   Lopez, Diana M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MUCIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VALYLSERYLISOLEUCYLGLYCYLLEUCYLSERYLPHENYLALANYLPROLYLMETHIONYLLEUCYL PROLINE MALEIMIDE ACTIVATED KEYHOLE LIMPET HEMOCYANIN CONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LEWIS CARCINOMA; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; CA-15-3 ANTIGEN; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS;

EID: 7444271027     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0853     Document Type: Article

References (44)

1. Lloyd KO, Burchell J, Kudryashov V, et al. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 1996;271:33325-34.
2. Agrawal B, Gendler SJ, Longenecker BM. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy. Mol Med Today 1998;4:397-403.
3. Taylor-Papadimitriou J, Epenetos AA. Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy. Trends Biotechnol 1994;12:227-33.
4. Fattorossi A, Battaglia A, Malinconico P, et al. Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells. Exp Cell Res 2002;280:107-18.
5. Correa I, Plunkett T, Vlad A, et al. Form and pattern of MUC1 expression on T cells activated in vivo or in vitro suggests a function in T-cell migration. Immunology 2003;108:32-41.
6. Taki C, Kitajima S, Sueyoshi K, et al. MUC1 mucin expression in follicular dendritic cells and lymphoepithelial lesions of gastric mucosa-associated lymphoid tissue lymphoma. Pathol Int 2002;52:691-701.
7. Wykes M, MacDonald KP, Tran M, et al. MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukoc Biol 2002;72:692-701.
8. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:565-77.
9. Carraway KL, Ramsauer VP, Haq B, et al. Cell signaling through membrane mucins. Bioessays 2003;25:66-71.
10. Zrihan-Licht S, Baruch A, Elroy-Stein O, et al. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett 1994;356:130-6.
11. Cerianì RL, Thompson K, Peterson JA, et al. Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci USA 1977;74:582-6.
12. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-63.
13. Sivinski CL, Kohlgraf KG, VanLith ML, et al. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunol Immunother 2002;51:327-40.
14. Chung MA, Luo Y, O'Donnell M, et al. Development and preclinical evaluation of a Bacillus Calmette-Guerin-MUC1-based novel breast cancer vaccine. Cancer Res 2003;63:1280-7.
15. Wreschner DH, Hareuveni M, Tsarfaty I, et al. Human epithelial tumor antigen cDNA sequences. Differential splicing may generate multiple protein forms. Eur J Biochem 1990;189:463-73.
16. Fu YX, Watson G, Jimenez JJ, et al. Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 1990;50:227-34.
17. Baruch A, Hartmann M, Zrihan-Licht S, et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer 1997;71:741-9.
18. Keydar I, Chou CS, Hareuveni M, et al. Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens. Proc Natl Acad Sci USA 1989;86:1362-6.
19. Rivera LM, Lopez DM. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors. Anticancer Res 1993;13:177-84.
20. Fu T, Shen Y, Fujimoto S. Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice. Int J Cancer 2000;87:680-7.
21. Watson GA, Lopez DM. Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995;155:3124-34.
22. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, et al. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 2003;171:4340-51.
23. Smorodinsky N, Weiss M, Hartmann ML, et al. Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies. Biochem Biophys Res Commun 1996;228:115-21.
24. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
25. Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002;7:209-21.
26. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA 1989;86:7159-63.
27. Finn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
28. Ioannides CG, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151:3693-703.
29. Moretta A, Bottino C, Vitale M, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
30. Gong J, Chen D, Kashiwaba M, et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 1998;95:6279-83.
31. Scholl SM, Balloul JM, Le Goc G, et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 2000;23:570-80.
32. Stacey KJ, Sester DP, Sweet MJ, et al. Macrophage activation by immunostimulatory DNA. Curr Top Microbiol Immunol 2000;247:41-58.
33. Jakob T, Walker PS, Krieg AM, et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998;161:3042-9.
34. Weiner GJ, Liu HM, Wooldridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-7.
35. Weiner GJ. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 2000;68:455-63.
36. Heikenwalder M, Polymenidou M, Junt T, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004;10:187-92.
37. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-54.
38. Bobek LA, Situ H. MUC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob Agents Chemother 2003;47:643-52.
39. Gururaja TL, Levine JH, Tran DT, et al. Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)1. Biochim Biophys Acta 1999;1431:107-19.
40. Kotera Y, Fontenot JD, Pecher G, et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994;54:2856-60.
41. Koido S, Tanaka Y, Chen D, et al. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 2002;168:2111-7.
42. Heukamp LC, van Hall T, Ossendorp F, et al. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002;25:46-56.
43. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 1999;48:47-55.
44. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 2003;24:58-61.